XML 28 R9.htm IDEA: XBRL DOCUMENT
v3.10.0.1

LIQUIDITY AND MANAGEMENT'S PLAN | 12 Months Ended
--- | ---
Sep. 30, 2018
Liquidity And Management Plan [Abstract] |
LIQUIDITY AND MANAGEMENT'S PLAN | NOTE A – LIQUIDITY AND MANAGEMENT’S PLAN Applied DNA Sciences, Inc. (the “Company”) has recurring net losses, which have resulted in an accumulated deficit of $248,366,083 as of September 30, 2018. The Company incurred a net loss of $11,692,928 and generated negative operating cash flow of $6,917,209 for the fiscal year ended September 30, 2018. At September 30, 2018 the Company had cash and cash equivalents of $1,659,564 and working capital of $1,180,185. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the financial statements. The ability of the Company to continue as a going concern is dependent on the Company's ability to further implement its business plan, raise capital, and generate revenues. The Financial Statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company’s current capital resources include cash and cash equivalents, accounts receivable and inventories. Historically, the Company has financed its operations principally from the sale of equity securities.

X
- References No definition available. + Details
Name: | apdn_LiquidityAndManagementPlanAbstract
Namespace Prefix: | apdn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure about liquidity and management plan. + References No definition available. + Details
Name: | apdn_LiquidityAndManagementPlanTextBlock
Namespace Prefix: | apdn_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration